Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market


4. Market Overview

4.1. Introduction

4.2. Key Industry Developments

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017–2027


5. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market, Key Insights

5.1. Clinical Trial Pipeline Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

5.2. Disease Prevalence: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

5.3. Major Deals & Strategic Alliances Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market


6. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast, by Drug Class

6.1. Key Findings

6.2. Introduction

6.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

6.3.1. TNF Inhibitors

6.3.2. Aminosalicylates

6.3.3. Integrin Antagonists

6.3.4. Corticosteroids

6.3.5. Others

6.4. Market Attractiveness Analysis, by Drug Class


7. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Disease Indication

7.1. Key Findings

7.2. Introduction

7.3. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

7.3.1. Ulcerative Colitis

7.3.2. Crohn’s Disease

7.4. Market Attractiveness Analysis, by Disease Indication


8. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Distribution Channel

8.1. Key Findings

8.2. Introduction

8.3. Market Value (US$ Mn) Forecast by Distribution Channel, 2019–2027

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Market Attractiveness Analysis, by Distribution Channel


9. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Region

9.1. Key Findings

9.2. Global Market Scenario

9.3. Market Value (US$ Mn) Forecast, by Region, 2019–2027

9.3.1. North America

9.3.2. Europe

9.3.3. Asia Pacific

9.3.4. Latin America

9.3.5. Middle East & Africa

9.4. Market Attractiveness Analysis, by Region


10. North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

10.1. Key Findings

10.2. Market Value (US$ Mn) Forecast, by Country, 2019–2027

10.2.1. U.S.

10.2.2. Canada

10.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

10.3.1. TNF Inhibitors

10.3.2. Aminosalicylates

10.3.3. Integrin Antagonists

10.3.4. Corticosteroids

10.3.5. Others

10.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

10.4.1. Ulcerative Colitis

10.4.2. Crohn’s Disease

10.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

10.5.1. Hospital Pharmacies

10.5.2. Retail Pharmacies

10.5.3. Online Pharmacies

10.6. Market Attractiveness Analysis

10.6.1. By Country

10.6.2. By Drug Class

10.6.3. By Disease Indication

10.6.4. By Distribution Channel


11. Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

11.1. Key Findings

11.2. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

11.2.1. Germany

11.2.2. U.K.

11.2.3. France

11.2.4. Italy

11.2.5. Spain

11.2.6. Rest of Europe

11.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

11.3.1. TNF Inhibitors

11.3.2. Aminosalicylates

11.3.3. Integrin Antagonists

11.3.4. Corticosteroids

11.3.5. Others

11.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

11.4.1. Ulcerative Colitis

11.4.2. Crohn’s Disease

11.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies

11.5.3. Online Pharmacies

11.6. Market Attractiveness Analysis

11.6.1. By Country/Sub-region

11.6.2. By Drug Class

11.6.3. By Disease Indication

11.6.4. By Distribution Channel


12. Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

12.1. Key Findings / Developments

12.2. Market Overview

12.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

12.3.1. China

12.3.2. India

12.3.3. Japan

12.3.4. Australia & New Zealand

12.3.5. Rest of Asia Pacific

12.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

12.4.1. TNF Inhibitors

12.4.2. Aminosalicylates

12.4.3. Integrin Antagonists

12.4.4. Corticosteroids

12.4.5. Others

12.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

12.5.1. Ulcerative Colitis

12.5.2. Crohn’s Disease

12.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

12.6.1. Hospital Pharmacies

12.6.2. Retail Pharmacies

12.6.3. Online Pharmacies

12.7. Market Attractiveness Analysis

12.7.1. By Country/Sub-region

12.7.2. By Drug Class

12.7.3. By Disease Indication

12.7.4. By Distribution Channel

13. Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

13.1. Key Findings / Developments

13.2. Market Overview

13.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

13.3.1. Brazil

13.3.2. Mexico

13.3.3. Rest of Latin America

13.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

13.4.1. TNF Inhibitors

13.4.2. Aminosalicylates

13.4.3. Integrin Antagonists

13.4.4. Corticosteroids

13.4.5. Others

13.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

13.5.1. Ulcerative Colitis

13.5.2. Crohn’s Disease

13.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

13.6.1. Hospital Pharmacies

13.6.2. Retail Pharmacies

13.6.3. Online Pharmacies

13.7. Market Attractiveness Analysis

13.7.1. By Country/Sub-region

13.7.2. By Drug Class

13.7.3. By Disease Indication

13.7.4. By Distribution Channel

14. Middle East and Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

14.1. Key Findings / Developments

14.2. Market Overview

14.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

14.3.1. GCC Countries

14.3.2. South Africa

14.3.3. Rest of Middle East and Africa

14.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

14.4.1. TNF Inhibitors

14.4.2. Aminosalicylates

14.4.3. Integrin Antagonists

14.4.4. Corticosteroids

14.4.5. Others

14.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

14.5.1. Ulcerative Colitis

14.5.2. Crohn’s Disease

14.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

14.6.1. Hospital Pharmacies

14.6.2. Retail Pharmacies

14.6.3. Online Pharmacies

14.7. Market Attractiveness Analysis

14.7.1. By Country/Sub-region

14.7.2. By Drug Class

14.7.3. By Disease Indication

14.7.4. By Distribution Channel

15. Competition Landscape

15.1. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Share, by Company, 2018

15.2. Market Player – Competition Matrix (By Tier and Size of companies)

15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

15.3.1. Pfizer, Inc.

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Product Portfolio

15.3.1.3. SWOT Analysis

15.3.1.4. Strategic Overview

15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Product Portfolio

15.3.2.3. SWOT Analysis

15.3.2.4. Financial Overview

15.3.2.5. Strategic Overview

15.3.3. Valeant Pharmaceuticals International, Inc.

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Product Portfolio

15.3.3.3. SWOT Analysis

15.3.3.4. Financial Overview

15.3.3.5. Strategic Overview

15.3.4. Allergan plc.

15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.4.2. Product Portfolio

15.3.4.3. SWOT Analysis

15.3.4.4. Financial Overview

15.3.4.5. Strategic Overview

15.3.5. Takeda Pharmaceutical Company Limited.

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Product Portfolio

15.3.5.3. SWOT Analysis

15.3.5.4. Financial Overview

15.3.5.5. Strategic Overview

15.3.6. AbbVie, Inc.

15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.6.2. Product Portfolio

15.3.6.3. SWOT Analysis

15.3.6.4. Financial Overview

15.3.6.5. Strategic Overview

15.3.7. Novartis AG

15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.7.2. Product Portfolio

15.3.7.3. SWOT Analysis

15.3.7.4. Financial Overview

15.3.7.5. Strategic Overview

15.3.8. UCB Inc.

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Product Portfolio

15.3.8.3. SWOT Analysis

15.3.8.4. Financial Overview

15.3.8.5. Strategic Overview

15.3.9. Biogen Inc.

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Product Portfolio

15.3.9.3. SWOT Analysis

15.3.9.4. Financial Overview

15.3.9.5. Strategic Overview



List of Figures



Figure 01: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017– 2027

Figure 02: Market Value Share, by Drug Class (2018)

Figure 03: Market Value Share, by Disease Indication (2018)

Figure 04: Market Value Share, by Distribution Channel (2018)

Figure 05: Market Value Share, by Country (2018)

Figure 06: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share analysis, by Drug Class, 2018 and 2027

Figure 07: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 08: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by TNF Inhibitors, 2017–2027

Figure 09: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Aminosalicylates, 2017–2027

Figure 10: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Integrin Antagonists, 2017–2027

Figure 11: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 12: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 13: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019–2027

Figure 14: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ulcerative Colitis, 2017–2027

Figure 15: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Crohn’s Disease, 2017–2027

Figure 16: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Distribution channel, 2018 and 2027

Figure 17: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness, by Distribution channel, 2019–2027

Figure 18: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 19: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 20: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2015-2025

Figure 21: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 22: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 23: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

Figure 24: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 25: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Country, 2019–2027

Figure 26: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 27: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 28: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 29: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 30: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019–2027

Figure 31: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 32: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027

Figure 33: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 34: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 35: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 36: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 37: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 38: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 39: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019–2027

Figure 40: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 41: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027

Figure 42: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 43: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 44: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 45: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 46: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 47: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 48: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019–2027

Figure 49: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 50: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027

Figure 51: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 52: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 53: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 54: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 55: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 56: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 57: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019–2027

Figure 58: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 59: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027

Figure 60: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 61: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 62: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 63: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 64: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 65: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 66: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2019–2027

Figure 67: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 68: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Share Analysis, by Company (2018)


List of Tables



Table 01: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 02: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 03: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 06: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 08: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 09: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 12: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 13: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 14: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 15: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 16: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 17: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 20: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 21: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027